Exporting OTC Drugs to the USA: FDA Guide

• Contents

To export over-the-counter (OTC) drugs to the United States, pharmaceutical manufacturers must comply with the regulations of the Food and Drug Administration (FDA). These requirements include aligning the product with a valid OTC monograph or obtaining approval through a New Drug Application (NDA), registering the manufacturing site via the agency’s electronic system (Establishment Registration), listing the drug with a National Drug Code (NDC), and adhering to current Good Manufacturing Practices (cGMP). Failing to meet any of these requirements will result in entry refusal by U.S. Customs and Border Protection (CBP).

The U.S. market for non-prescription (over-the-counter or OTC) medicines generates billions of dollars annually. It represents a commercial opportunity for manufacturers with established formulas such as pain relievers, topical antiseptics, medicated sunscreens, and antacids. However, entering this market requires technical precision: the FDA does not classify OTC items as ordinary consumer goods, but as pharmaceuticals subject to safety, efficacy, and labeling controls.

OTC Monograph vs. New Drug Application (NDA)

When planning market entry into the United States, the first strategic step is determining the regulatory pathway for the product. The FDA provides two primary routes for marketing non-prescription drugs:

The fastest and most cost-effective path for most exporters is the OTC Monograph. Monographs function as pre-established regulatory blueprints: administrative standards that identify active ingredients, dosages, combinations, indications, and warning statements recognized as Generally Recognized as Safe and Effective (GRASE). If a formulation, dosage, and labeling are 100% compliant with an existing monograph, the product can bypass the individual pre-market clinical review and approval process.

Conversely, if a drug contains an active ingredient new to the U.S. market, introduces an unlisted combination, or features a modified dosage form, it must pursue a New Drug Application (NDA) or an Abbreviated New Drug Application (ANDA). This pathway requires clinical and non-clinical dossiers, substantial regulatory user fees, and evaluation timelines that typically range from 12 to 18 months or longer.

The Modernization of OTC Monographs (CARES Act)

For decades, updating FDA monographs involved cumbersome administrative rulemaking. That changed with the passage of the CARES Act, which reformed Section 505G of the Federal Food, Drug, and Cosmetic Act (FD&C Act).

This reform replaced prolonged rulemaking with streamlined Administrative Orders, accelerating updates to safety standards and the incorporation of modern scientific data. Additionally, the statute instituted the Over-the-Counter Monograph Order Request (OMOR) process and established the OTC Monograph User Fee Program (OMUFA).

Under OMUFA, facilities that manufacture or process finished OTC drug products for U.S. distribution are subject to mandatory annual facility fees. Failure to pay these fees leads to registration suspensions and regulatory penalties. Maintaining financial and regulatory tracking is a core element of international corporate compliance.

Ensuring your manufacturing facility and analytical data adhere to U.S. standards requires specialized regulatory expertise. To expedite both production compliance and commercial readiness, manufacturers often partner with FDA OTC regulatory specialists—such as the team at B2B TradeCenter—who assist pharmaceutical facilities throughout the entire FDA compliance process.

Step-by-Step Regulatory for Exporting

Regulatory compliance with the FDA is electronic and interconnected with CBP border systems. The core compliance include:

1. Appointing a U.S. Agent: Foreign establishments must designate an official legal agent residing in the United States to serve as the primary liaison between the FDA and the manufacturer.
2. Facility Registration (Establishment Registration): An annual mandatory electronic registration via Structured Product Labeling (SPL). It must be renewed each year between October 1 and December 31.
3. Drug Listing: Every exported drug product, strength, and packaging configuration must be submitted via SPL, including full quantitative composition, labeling artwork, and packaging specifications.
4. National Drug Code (NDC) Assignment: Each listed product receives a unique 10- or 11-digit identifier segmenting the labeler code, product code, and package code.
5. cGMP Compliance Auditing (21 CFR Part 211): The supply chain must demonstrate validated manufacturing processes, quality control release testing, sanitation control, and batch stability protocols.

For companies seeking to safely expand their global market presence through secure international contracts, the trade advisory team at B2B TradeCenter provides tailored assistance in structuring cross-border supply agreements and building durable distribution partnerships.

Strict Standards of the Drug Facts Label

Packaging and labeling non-compliances are the leading cause of refused entries and import holds at U.S. ports of entry (Import Alerts). The U.S. regulatory framework mandates that all OTC pharmaceuticals strictly conform to the Drug Facts Label formatting standards governed by 21 CFR 201.66.

This regulation defines typographic sizes, weights, background contrast, hairline borders, and exact information sequencing. The panel must present the following sections in order:

• Active ingredient(s): Name and quantitative amount per dosage unit.
• Purpose: Pharmacological category or therapeutic role of the active ingredient.
• Uses (Indications): Symptoms, conditions, or targets the medication treats, mitigates, or prevents.
• Warnings: Required cautionary language, vulnerable population notices (pregnancy, nursing, pediatric), contraindications, and instructions on when to discontinue use.
• Directions: Dosage amounts, specific age brackets, dosing intervals, and maximum daily limits.
• Other information: Storage conditions (temperature, humidity limits) and declared electrolyte contents (e.g., sodium, calcium, magnesium), where applicable.
• Inactive ingredients: Comprehensive list of excipients, organized either alphabetically or in descending order of predominance.
• Questions or comments?: Customer service contact details, including a valid U.S. telephone number.

No external marketing claims, promotional slogans, or cosmetic language may contradict, distort, or exceed what is authorized under the respective monograph. Unsubstantiated claims cause the product to be categorized as "misbranded" or an "unapproved new drug," leading to regulatory seizure.

Customs Clearance, Holds, and Managing Import Alerts

Upon arrival at U.S. ports of entry or international air hubs, U.S. Customs and Border Protection (CBP) officers screen commercial invoices, bills of lading, and shipping manifests through the FDA’s automated PREDICT screening algorithm.

If the system flags discrepancies in label statements, a lack of recent inspection history, unpaid OMUFA fees, or an invalid NDC, the shipment receives a Notice of FDA Action and is placed on physical hold.

In severe scenarios, a foreign manufacturer or product line may be subjected to an Import Alert (Detention Without Physical Examination - DWPE). Once listed, all future shipments from that facility are automatically refused at the border until the firm submits a comprehensive petition demonstrating sustained corrective action. Resolving an import alert often takes months, runs up demurrage fees, and damages international client trust.

Should an administrative detention occur, the manufacturer must execute an immediate legal and regulatory response. Formal petitioning to the agency is the sole viable recourse. B2B TradeCenter’s FDA Import Alert removal team assists international manufacturers in drafting technical petitions, organizing audit documentation, and clearing red-list classifications to restore seamless trade.

The most reliable safeguard remains systematic compliance: harmonizing tariff schedules (HS/HTS codes), maintaining validated Certificates of Analysis (CoA) for every batch, and verifying cGMP standards in tandem with cross-border trade advisors.

Frequently Asked Questions (FAQ)

What happens if our overseas manufacturing site has not been inspected by the FDA prior to shipping?
The FDA does not mandate an on-site facility inspection prior to initial commercial import, provided the facility is registered and actively operating in full compliance with cGMP (21 CFR Part 211). However, the agency reserves the right to conduct routine or unannounced inspections at foreign facilities, or to issue an electronic records request. Refusing or failing an inspection will place the facility on an Import Alert, barring shipments from entering the country.

Are sunscreens and anti-dandruff shampoos treated as OTC drugs by the FDA?
Yes. In the United States, personal care products containing active ingredients formulated to treat, mitigate, or alter biological structures or functions are regulated as pharmaceuticals, not cosmetics. This includes sunscreens (regulated under the Sunscreen Monograph), anti-dandruff hair care products containing zinc pyrithione or salicylic acid, and antiperspirants using aluminum salts. All require active NDC numbers, registered manufacturing facilities, and standard Drug Facts labels.